Daisuke Hazeki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daisuke Hazeki has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Kentaro Ueno
Department of Pediatrics Kagoshima University Hospital Kagoshima Japan
2 shared publications Hiroki Iwaizako
Department of Pediatrics, Kagoshima City Hospital, Kagoshima, Japan
1 shared publication- Junpei Kawamura
Department of Pediatrics Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima Japan
1 shared publication Kensuke Horinouchi
Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8544, Japan
1 shared publication- Masaki Kusuda
Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
1 shared publication - Shinsuke Maruyama
Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan
1 shared publication
Latest Publications
- Open Access
- 15 July 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (8)
Clinical factors associated with retreatment and early coronary outcomes in Kawasaki disease in children aged < 6 months: a single-center cohort study
To evaluate whether pre-treatment coronary artery aneurysm (CAA) Z-score, inflammatory markers, and incomplete Kawasaki disease (KD) status are associated with intravenous immunoglobulin (IVIG) retreatment and early coronary outcomes in infants aged < 6 months. We retrospectively reviewed infants aged < 6 months who were treated with IVIG for KD between 2011 and 2024. Clinical, laboratory, treatment, and serial echocardiographic data were collected, and patient-level maximal coronary Z-scores were calculated. The primary outcome was additional IVIG; the secondary outcome was CAA Z-score (≥ 2.5) at approximately 1 month after illness onset. Among 76 infants (median age, 4.3 months), 17/76 (22.4%) required additional IVIG, 14/76 (18.4%) had CAA at approximately 1 month after illness onset, and 3/76 (3.9%) had residual CAA at or after 6 months. Additional IVIG was independently associated with pre-treatment CAA (Z ≥ 2.5), earlier illness day at initial IVIG, and higher neutrophil-to-lymphocyte ratio; the multivariable model showed good discrimination (area under the curve [AUC] 0.84). For CAA at 1 month, both a baseline-only model including pre-treatment CAA Z-score, albumin, and illness day at initial IVIG (AUC 0.91, 95% confidence interval [CI] 0.84-0.97) and a course-aware model including pre-treatment CAA Z-score and additional IVIG (AUC 0.90, 95% CI 0.84-0.97) showed high discrimination. CAA at 1 month with Z-max ≥ 5.0 was associated with residual CAA risk. In infants aged < 6 months with KD, pre-treatment coronary involvement and higher inflammatory burden were strongly associated with additional IVIG, whereas pre-treatment coronary disease severity, lower albumin, and an early refractory course were strongly associated with CAA at 1 month. • Infants aged < 6 months with Kawasaki disease (KD) have higher non-response to intravenous immunoglobulin (IVIG) and more coronary artery abnormalities (CAA). • Guidelines recommend early transthoracic echocardiography and coronary Z-score assessment, but infant-specific prognostic data remain limited. • In this infant-only cohort, pre-treatment CAA Z-score ≥ 2.5 and neutrophil-to-lymphocyte ratio ≥ 2.15 were associated with additional IVIG. • Pre-treatment CAA Z-score, lower albumin, and an early refractory course were the factors most strongly associated with CAA at 1 month.
- 15 July 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (8)
Open AccessClinical factors associated with retreatment and early coronary outcomes in Kawasaki disease in children aged < 6 months: a single-center cohort study
To evaluate whether pre-treatment coronary artery aneurysm (CAA) Z-score, inflammatory markers, and incomplete Kawasaki disease (KD) status are associated with intravenous immunoglobulin (IVIG) retreatment and early coronary outcomes in infants aged < 6 months. We retrospectively reviewed infants aged < 6 months who were treated with IVIG for KD between 2011 and 2024. Clinical, laboratory, treatment, and serial echocardiographic data were collected, and patient-level maximal coronary Z-scores were calculated. The primary outcome was additional IVIG; the secondary outcome was CAA Z-score (≥ 2.5) at approximately 1 month after illness onset. Among 76 infants (median age, 4.3 months), 17/76 (22.4%) required additional IVIG, 14/76 (18.4%) had CAA at approximately 1 month after illness onset, and 3/76 (3.9%) had residual CAA at or after 6 months. Additional IVIG was independently associated with pre-treatment CAA (Z ≥ 2.5), earlier illness day at initial IVIG, and higher neutrophil-to-lymphocyte ratio; the multivariable model showed good discrimination (area under the curve [AUC] 0.84). For CAA at 1 month, both a baseline-only model including pre-treatment CAA Z-score, albumin, and illness day at initial IVIG (AUC 0.91, 95% confidence interval [CI] 0.84-0.97) and a course-aware model including pre-treatment CAA Z-score and additional IVIG (AUC 0.90, 95% CI 0.84-0.97) showed high discrimination. CAA at 1 month with Z-max ≥ 5.0 was associated with residual CAA risk. In infants aged < 6 months with KD, pre-treatment coronary involvement and higher inflammatory burden were strongly associated with additional IVIG, whereas pre-treatment coronary disease severity, lower albumin, and an early refractory course were strongly associated with CAA at 1 month. • Infants aged < 6 months with Kawasaki disease (KD) have higher non-response to intravenous immunoglobulin (IVIG) and more coronary artery abnormalities (CAA). • Guidelines recommend early transthoracic echocardiography and coronary Z-score assessment, but infant-specific prognostic data remain limited. • In this infant-only cohort, pre-treatment CAA Z-score ≥ 2.5 and neutrophil-to-lymphocyte ratio ≥ 2.15 were associated with additional IVIG. • Pre-treatment CAA Z-score, lower albumin, and an early refractory course were the factors most strongly associated with CAA at 1 month.
- 19 January 2020
- Published by Wiley in Pediatrics International
- Vol. 62 (1) , 96-97
Right‐ventricular outflow tract obstruction by adrenocorticotrophic hormone therapy for infantile spasms after Norwood operation
- 19 January 2020
- Published by Wiley in Pediatrics International
- Vol. 62 (1) , 96-97
Right‐ventricular outflow tract obstruction by adrenocorticotrophic hormone therapy for infantile spasms after Norwood operation